home truths, page-46

I would certainly also welcome news which finally set clear targets for the near future.

As for agendas, steering clear of them, neutralising them or use them for your own purposes is a fact of life in management.
Often it is quite possible to direct agendas straight back at the people who have initiated them, it takes a good player not to be caught eventually in his own cleverness.


Revealing testing results would be something any of the large players, in my opinion, would be reluctant to publish before they determined the right moment to do so.
As I see it, the transdermal delivery market is undergoing
both vast expansion as well as fundamental change in its delivery techniques.
In this context I understand that companies do protect their testing and research results as a lot of money will be made by the one who gets there first.
The one large player who will innovate its delivery applications ahead of the competition will walk away with a market advantadge.
As it stands currently I do expect several innovations to be implemented simultaneously, depending what drug delivery in particular they offer.
This enhanced competitive nature explains to me the ongoing secrecy, taken into account how huge the market is in revenue terms world wide.

Wether OBJ will be part of this industry innovation or miss out in the end with others stepping up earlier is hard to say. All we can go by is the fact that all major companies so far involved with OBJ have not walked away and keep showing interest which is now long term by all 3 companies, 3M, GSK and the FMCG.

Initially I invested in this company because I was excited by the outlook of the technology and its vast possible applications, then encouraged by testing and research results published and eventually supported in my interest by large companies surrounding this technology.

Unless I hear otherwise, I enjoy to be part of this industry changing process.